-
Record FDI flow into Greece raises bar, but is it sustainable?
-
Balance of payments shows shipping on course for bumper year, but economic benefits unclear
-
One unicorn does not a Silicon Valley make: positive news on startup front also highlights limitations
-
Impact of inflation already widespread, but data suggests worse to come
-
Discussion over PEPP, SGP draw attention to rising yields
-
Post-Covid era dawns on new landscape for bad debt in Greece
Greek Pharmaceuticals: The little pill with big potential
The Greek pharmaceutical industry has remained a relatively strong sector despite the crisis - it contributes around 2.8 billion euros to GDP annually, according to the Greek government, and is one of the few industries in Greece which expanded its companies and workforce during the crisis rather than reduced it.
In export terms, Greek medical products (packaged medicaments) come second only to refined petroleum products. With a highly skilled workforce and reliable reputation in the sector, the Greek pharma industry has grounds for expanding its market share in...
You need a subscription to access our analysis. Please choose one of the packages available.
Full Access
A tailor-made service for professionals
Apart from having access to all our analysis and data, subscribers will be able to consult one-on-one with our analysts.
Free Access
Read some of our analysis for no charge
By signing up to MacroPolis, readers will be able to read two of our articles without charge each month. They will not have access to our data or weekly e-newsletter.
Standard Access
Our analysis and data at your fingertips
Subscribers will be able to read the full range of our articles, access our statistics and charts, and receive our weekly e-newsletter for €450 per year.
€500.00